Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buy the dip! Big news coming!!!!!
This is not going any lower then $4ish so if you are an investor i would strongly recommend adding here.
Like I said, people got spooked by the RS. Other then the RS, nothing else has changed to warrant the decline in PPS. After the uplist to the nasdaq, it will open the door to many institutional investors that can’t purchase otc stocks.
Yes, the company just got a 6 million dollar grant and the market cap is only 12 million right now. Way undervalued so now is the time to buy.
It’s going much higher than that. Some people got spooked by the reverse split but, there are great things coming
Yup - now is the time to buy. I loaded up in the mid 3.50 - 4 range last week. I bet we are back over 6 in a couple weeks.
When investors lose most of their investment it’s not worth selling unless they want the tax write off. They just hold on to it in hopes that one day they will break even. I have a grave yard of penny stocks worth almost nothing, including VLDI.
“Clean up the books”. Buyout coming - Lol. That was 2 years ago.
No shareholder meeting. No sales. No nothing. Same old BS 6 years and counting.
After 20 years I would hardly call it a start up anymore
I don’t remember ever reading anything about a buy out in any PR released by the company. I do remember reading about many installs and potential sales that never happened over the past 7 years. You don’t find that strange?
NDAs. Lol!
After some time, you realize nothing about this company makes any sense or adds up. I was the same as you about 6 years ago. Glad and are finally realizing that.
So you have earth shattering DD that would send the stock sky rocketing and you don’t want to share it? I guess you are following Bruce’s playbook. LOL
Why not share some with us? I need some positive information to offset all the red VLDI has tainted my portfolio with.
When you are down 95% on your investment and being fed the same BS for the past 7 years, it’s hard to keep your eye on the ball anymore.
Bc he prob dumped the shares he was given to write that recommendation.
Take over what? The company doesn’t have anything of value. Only debt.
Good luck. Glad you are finally starting to see the light. It took me a few years.
Haven’t you been here long enough now to realize nothing ever comes to fruition with this company?
The company can’t pick the dates for the RS and grant award notification. It was just a coincidence they both happened on the same day. They have to report those events when they happen. Plain and simple.
They got the grant. 5.5 million over 2 years!
People here think being down 95% on their investment for the past 5 years is no big deal. lol
Lol - been here for over 6 years and nothing EVER happens. What has changed?
All of this information is in the past few updates from the company. Check the the website for past updates, which have been posted at least once a month.
Dump - paint
Dump - paint
Dump - paint
Lol
Great article!
GREAT NECK, N.Y. (PRWEB) DECEMBER 07, 2018
Ever more effective therapies for drug addiction – a life-threatening brain disorder – may be on the horizon as scientists, physicians and commercial enterprises partner to respond to the national crisis involving abuse of pain-relieving medications, called opiates.
In fact, one particularly potent weapon – a new approach to delivering the effective treatment drug, naltrexone, in an implantable, longer-lasting format – is already in the clinical study queue and could be given the FDA’s go-ahead soon for widespread use by physicians, says Dr. Russell Surasky, FAAN, ABPM.
He calls this innovative, implantable drug therapy a potential “game-changer” for any patient addicted to opiates or alcohol.
Dr. Surasky is a noted brain specialist, who holds rare, double-board certifications in neurology and addiction medicine and serves as medical director of Bridge Back to Life, a multi-center outpatient addiction treatment program. He also founded the Surasky Neurological Center for Addiction in Great Neck, New York and is a national speaker, educating physicians and the New York criminal justice system about addiction and its treatment.
“Statistics show that, each day, some-4,000 people in the United States begin abusing opiates; another 400 individuals start using heroin. Their brain disorder – addiction – results in an estimated 120 drug-overdose deaths daily,” states Dr. Surasky.
Dr. Surasky provides an overview of the opioid-abuse problem and resulting addiction and shares his knowledge of currently available and future treatments.
Q. What does the most recent research tell us about addiction?
A. Each of us has two brain centers: the rational brain and the limbic system. The limbic system is the most powerful driver of human behavior, controlling basic survival needs like eating, drinking and mating and functioning outside conscious control. No messages from our rational brain can restrain it. The use of opioids hijacks the limbic system. Opiates bind directly to brain receptors, thereby rewiring the brain and reordering its survival priorities so that opioid drugs become the primary motivator in life.
Q. What treatments are currently in use to manage addiction disorders?
A. Suboxone and methadone are drugs commonly used to treat opiate addiction. They reduce overdoses, but, unfortunately, both also are extremely addictive. With suboxone and methadone, the brain does not have a chance to return to its normal number of opiate receptors, thus forcing the patient to remain reliant on addictive substances. The emotional centers of the brain are not allowed to reset; the mind continues to create memories in presence of an opiate. This process continues the craving and obsession that fuel relapses and perpetuate the addictive cycle. Essentially, suboxone and methadone are a trade-off, offering short-term benefits with long-term consequences. Without newer treatments to replace them, we soon will be left with countless patients physically dependent on these drugs.
Q. Thanks to some innovative approaches, you have achieved success in treating addictions. Can you tell us more?
A. At our addiction center, we have developed a treatment program centered on the medication naltrexone. Unlike suboxone and methadone, naltrexone is not an opiate, is not addictive, and does not cause physical dependence. It attaches to opiate receptors in the patient’s brain and immediately and dramatically reduces cravings for opiates. Even if patients abuse opiates while on naltrexone therapy, they neither experience a “high” nor do they become sick. Additionally, naltrexone does not require a life of unending medication. Treatment length varies, but typically continues for approximately one year.
As part of our program, we have developed a new protocol that involves use of neurologic-based medications just prior to the start of naltrexone treatment. These neurologic medications completely eliminate opiate withdrawal symptoms, allowing the patient to start naltrexone treatment (Vivitrol or implantable) within just a couple of days without having to go first through difficult opiate withdrawal symptoms.
Currently, naltrexone is given in an injectable form, called Vivitrol. The effectiveness of each injection lasts only about one month, requiring the patient to follow up with a doctor on a regular basis. The first few months of sobriety are the most critical and challenging for patients. Having a drug delivery mechanism that can prolong the benefits of Vivitrol well beyond a month would be ideal.
Q. Do you see something better on the horizon?
A. The addiction treatment company, BioCorRx, is developing a sustained-release naltrexone implant. The implant -- BICX102 -- would be embedded under the skin, allowing release of naltrexone continuously for approximately three months. A product like this could make a huge difference in the lives of patients undergoing treatment for opiate or alcohol addiction,
Q. For sake of disclosure, do you invest in, or work for, Alkermes, BioCorRx or other enterprises related to your work as an addiction specialist?
A. The pharmaceutical company, Alkermes, recently sponsored my efforts to teach other physicians in the country about addiction and Vivitrol therapy – an opportunity for which I am truly grateful. I do invest in many companies that have goals aligning with the values and principles of serving humanity including BICX. I believe Vivitrol and the development of the naltrexone implant, BICX 102, could prove a significant leap forward in our work as physicians to relieve the suffering of addiction.
Noted brain specialist Dr. Russell Surasky serves as medical director of Bridge Back to Life, a multi-center outpatient addiction treatment, and is founder of the Surasky Neurological Center for Addiction in Great Neck, N.Y. He holds rare, double-board certifications in neurology and addiction medicine and is well known for his innovative approaches to the treatment of addiction and mental illness. His memberships in professional organizations include the American Academy of Neurology and the American Society of Addiction Medicine. https://www.drsurasky.com/
https://www.prweb.com/releases/more_effective_treatment_options_for_addiction_on_horizon/prweb15973057.htm
Nice 260K share bid at .075 today.
I bought more shares last week in the .06 area. It’s only a matter of time before the grant is awarded. I bet this is old legacy shareholders selling that brought the price down.
Many investors accumulating shares at these prices. The grant is coming from a government agency, which always takes much longer than expected. I am confident we will get news of the grant before Santa comes down the chimney.
Don’t miss the pump!
I doubt fb is doing anything with Validian. Makes for a good PR though.
He comes the run back to .15 - get ready.
Anyone know what score they got from NIDA for the grant?
Just bought more shares on the dip. NIDA grant in eminent.
smells like a pump and dump
Anyone know what score they got from NIDA for the grant ?
read the last few PRs. They mentioned it in almost everyone one of them.
Wow - stock is down to .20 premarket.
You should check out BICX. They have a fresh new neltrexone implant up for FDA approval.